NOTE B – Liquidity, Plan of Operations and Going Concern

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles.

The Company has experienced net losses and negative cash flows from operations each period since its inception. Through September 30, 2017, the Company had an accumulated deficit of approximately $47.6 million. The Company’s operations have been financed primarily through the sale of equity securities. The Company’s net loss for the nine months ended September 30, 2017 and 2016 was approximately $11.9 million and $5.7 million, respectively.

The Company has been engaged in developing a pipeline of product candidates since 2011. To date, the Company has not obtained regulatory approval for any of its product candidates nor generated any revenue from products and the Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in any indication in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability.

Assuming the Company obtains FDA approval for one or more of its product candidates, which the Company does not expect to receive until 2022 at the earliest, the Company expects that its expenses will continue to increase once the Company reaches commercial launch. The Company also expects that its research and development expenses will continue to increase as it moves forward with additional clinical studies for its current product candidates and developing additional product candidates. As a result, the Company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing.

To continue to fund its continued losses, on January 13, 2017, the Company completed a warrant tender offer, with gross cash proceeds of $13.5 million and net proceeds of approximately $12.7 million (see Footnote E for additional details). Additionally, the Company has entered into a Controlled Equity Offering^SM Sales Agreement with Cantor Fitzgerald & Co. “Cantor” ( see Footnote C), which allows the Company, subject to certain limited restrictions and daily sales limits, to sell shares of common stock having an offering price of up to $30 million. Through October 19, 2017, the Company has sold approximately 871 thousand shares of common stock pursuant to the Controlled Equity Offering^SM Sales Agreement with Cantor raising over $1.1 million (see footnote C).

As of September 30, 2017, the Company had cash and cash equivalents of approximately $ 9.0 million. We believe the cash and cash equivalents on hand are sufficient to fund planned operations through May 2018.

The ability of the Company to continue as a going concern is dependent upon securing additional financing. While the Company believes in the viability of its strategy to raise additional funds, and believes that the actions presently being taken by the Company provide the opportunity for it to continue as a going concern, there can be no assurance that any financing will be available on acceptable terms, or at all. These consolidated financial statements do not include any adjustments related to the recoverability and classification of asset amounts or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.